Category: Business

(SeaPRwire) - Most 3D printing hobbyists and small-shop operators treat filament drying like an afterthought until a print fails midway through a twenty-hour job. Stringing, surface bubbling, and brittle extrusion are usually blamed on bad slicer settings or nozzle clogs, while the real culprit is ambient humidity quietly ruining the polymer spool sitting out on the rack. The recently announced eSUN eBOX Plus aims straight at this persistent workshop headache by scaling up capacity and automating active dehumidification for everyday FDM workflows.Looking closer at the hardware specs released by Wuhan-based eSUN on October 23, 2026, the device introduces some practical engineering choices tailored for multi-material users. Traditional single-spool dryers force a frustrating bottleneck when juggling different colors or engineering polymers. The eBOX Plus addresses this by expanding its internal chamber to accommodate up to four spools of the same filament type simultaneously, cutting down on repetitive drying cycles. Heating capabilities reach a maximum of 80°C, which covers standard workshop materials like PLA, PETG, ABS, and TPU, provided operators dial in the correct thermal profiles for each specific polymer.Beneath the hood, the system moves past passive desiccant storage by deploying dual PTC heating elements paired with dual fans. This setup drives a 360-degree airflow pattern to keep the thermal environment uniform. More importantly, an intelligent active dehumidification system continuously monitors internal chamber humidity and purges the moisture rather than letting it linger inside the enclosure. For those who prefer backup options, an independent, removable desiccant box is included. The integrated dry-while-printing function also lets users feed filament directly from the warm chamber to compatible 3D printers, which minimizes ambient exposure during extended jobs. Master Mode rounds out the software side by offering preset parameters for common filaments, skipping manual configuration for straightforward print jobs.Ultimately, hardware like this reflects a quiet maturation in desktop fabrication where material handling matters just as much as extruder mechanics. As long as hygroscopic polymers remain a staple of daily production, standalone dryers will evolve from optional accessories into mandatory infrastructure for reliable builds.

(SeaPRwire) - Every major pharmaceutical company has a tech partnership press release waiting in its backlog. Boehringer Ingelheim and Microsoft just released theirs. The announcement covers Digital Patient Twins, synthetic control arms, disease-progression modeling, and workforce-wide AI transformation. The headline promises faster access to safe and effective therapies. The subheading promises patient-centric, AI-backed clinical development. What it does not mention is the fact that this is another in a long string of such partnership announcements in the last eighteen months. The pattern is always the same. Two large companies meet in Germany or Boston. They sign a strategic collaboration. They issue a joint statement about bringing therapies to patients sooner. Eighteen months later, no drug has been approved faster because of it. The infrastructure gets built. The models get trained. The press releases keep coming. The regulatory pathway does not change. Investors love the partnership narrative. Analysts love the digital transformation story. Patients, who are the stated beneficiaries of every one of these collaborations, remain patient. Because they are still waiting. The official announcement describes an ambitious scope. Boehringer Ingelheim has stated a clear ambition to become a Frontier AI company across both human pharmaceuticals and animal health. The company has already deployed one of the largest Microsoft Copilot implementations in the pharmaceutical sector. The partnership covers security and datacenter modernization, supporting a secure, resilient, and future-ready technology foundation. They are exploring co-development projects in animal health, business processes, and technology infrastructure. Microsoft Germany employs over 3,000 people across seven locations: Berlin, Frankfurt, Hamburg, Cologne, Munich, Stuttgart, and Waldf. Boehringer Ingelheim has approximately 54,300 employees serving over 130 markets. The company has been independent since 1885. The commitment to employee enablement is explicit, with role-based use cases, skills development, governance, and secure technology foundations. The infrastructure investment is real. The workforce training budget is real. But the industry subtext cuts through the announcement language quickly. Deploying Microsoft Copilot across a workforce does not change regulatory timelines. Building datacenters does not change the FDA's evidentiary standards. Expanding into animal health and business processes does not accelerate human drug approvals. These are operational investments, not clinical breakthroughs. The security and datacenter modernization piece is not trivial either. AI models that process patient data need robust, compliant infrastructure. Building that foundation is necessary work. But it is also work that every major pharmaceutical company is doing independently or with its cloud partner of choice. This is table-stakes infrastructure, not a competitive differentiator. The first half of the partnership is solid. It is also largely irrelevant to the question of whether patients get medicines faster. The clinical development goals are where the tension lives. The official facts describe a joint research program exploring disease-progression modeling, predictive outcome modeling, and advanced trial simulation. The starting point is lung health, with plans to extend across multiple disease and therapeutic areas. Digital Patient Twins are computational representations of individual patients that use clinical and other relevant data to predict disease progression and treatment outcomes. The partnership will assess scientific and technical feasibility through modeling, prototyping, and evidence generation. The stated goals include reducing the number of patients required in control groups. They want to accelerate the generation of clinical evidence. They want to improve clinical trial design. They are exploring whether these approaches could support synthetic or hybrid control arms. Synthetic control arms use existing real-world data. Hybrid control arms combine real-world data with a traditional control group. These are all legitimate and important research directions. But the subtext is where the partnership meets its ceiling. The FDA has issued guidance on using external data in clinical trials. The EMA has published its own position papers. Neither agency has formally accepted synthetic control arms as a primary comparator for new therapeutic approvals in major therapeutic areas. The FDA guidance allows for use in certain circumstances, particularly rare diseases where recruitment is difficult. For common therapeutic areas, regulators still insist on placebo-controlled or active-comparator designs. The disease-progression modeling angle is particularly nuanced. Predicting how a disease like COPD or emphysema progresses in an individual patient is a hard problem. Even good models have uncertainty bands. And regulatory agencies are not comfortable with evidence generated from models with meaningful uncertainty. The hybrid control arm approach is more conservative by design. It still requires some traditional patient enrollment in the control group. That reduces but does not eliminate the regulatory friction. A company can build the most sophisticated Digital Patient Twin in the world. If the FDA or EMA does not accept the output as evidence for regulatory approval, the tool remains a research artifact. The bottleneck is not computing infrastructure. The bottleneck is not model accuracy. The bottleneck is institutional regulatory conservatism. No partnership between a pharmaceutical company and a cloud provider changes that assessment. The drug development supply chain has not changed structurally in a decade. Trials still take seven to ten years. Still require thousands of enrolled patients. Still face regulatory review timelines that vary by jurisdiction but rarely move faster. The partnership between Boehringer Ingelheim and Microsoft is not a failure. It is simply one node in a pipeline that is constrained by regulatory gatekeeping. The tools they build might inform trial design. They might improve predictive modeling. They might contribute to evidence generation in specific scenarios. But they will not collapse the approval timeline unless regulators change course. The pharma-AI partnership market has become a signaling mechanism. Companies announce alliances to signal to investors and analysts that they are investing in digital transformation. That signaling has value in the short term. It has almost no value in the long term unless the underlying regulatory environment shifts. The drug development pipeline is not just a technology problem. It is a regulatory problem. And regulators do not move at the speed of cloud partnerships. They move at the speed of peer-reviewed evidence, stakeholder consultations, and multi-year guidance updates. That is the supply chain reality that no press release can change. The industry needs to face this directly. Every pharma-to-cloud partnership announcement creates the expectation that technology will solve what is ultimately a policy problem. It will not. The next time a pharmaceutical company partners with a hyperscaler to accelerate drug development, ask one question. Has the FDA or EMA updated their guidance on computational control arms since the last announcement? The answer will be no. Until that answer changes, the partnership announcements are infrastructure spending ahead of regulatory policy. The patients who need faster drug access will keep waiting.

(SeaPRwire) - Let's be honest. When a mid-tier wealth manager rebrands, nobody cares about the logo refresh. The real question is whether they're pivoting from a niche position they can't defend to a broader play they might actually win. Abbott International is doing exactly that. They spent 2026 consolidating their corporate structure, bringing domain alignment in April, and launching a new website in July. That's not aesthetics. That's triage. The press release frames this as an evolution. "From primarily investment-focused toward a broader wealth management model." Read between the lines. Investment management alone is a low-margin game with razor-thin differentiation. Every family office, every boutique firm, every global bank does it. The real money in wealth management isn't managing portfolios. It's managing relationships. It's fee-based planning that sticks. That's what Abbott is reaching for. The CEO, Jianyu Luo, says the company has developed considerably over the past year. "Developed" is generous coding for restructuring. The consolidation of corporate assets, digital properties, and intellectual property under one structure suggests they were fragmented before. Fragmentation kills valuation. The official facts are straightforward. The abbottinternational.com domain was unified in April 2026. The new corporate website went live in July. Investment management, wealth planning, and client services now sit under one identity. The revised offering targets clients across different markets and financial circumstances. The company works with individuals, families, and institutions. They emphasize long-term client relationships and integrated services. Nothing controversial there. But the industry subtext is clear. The wealth management space in Greater China and the broader Asian corridor is among the most crowded in the world. You either differentiate through technology, through scale, or through positioning that nobody else owns. Abbott is betting on positioning. They're trying to become the firm that treats investment decisions as one piece of a larger financial life picture. That's a defensible niche if you execute well. What I want to know is whether this rebrand actually changes anything on the ground. Clients don't care about your domain strategy. They care whether their advisor understands their tax situation, their succession plans, their liquidity needs. The press release mentions all of this. But execution is everything. And execution requires people who aren't just investment managers wearing wealth planner hats. It requires genuine multi-disciplinary capacity. That's hard to build. That's harder to keep. The China angle is significant. Abbott is explicitly developing business there while maintaining an international footprint. That's a double-edged strategy. Chinese high-net-worth clients are sophisticated. They've worked with UBS, with Credit Suisse, with local state-backed firms. A rebrand won't impress them. A track record will. And that takes years, not a new website launch. Here's my assessment. The rebrand is real. The restructuring behind it is real. But the competitive landscape hasn't shifted by a single degree because of it. Abbott International is now better positioned to compete in the broad wealth management segment. That doesn't mean they'll win there. It means they've entered the fight. The market share reshuffling will depend on whether they can convert this corporate realignment into actual client acquisition and retention gains over the next 18 to 24 months. Watch their client numbers, not their press releases.

(SeaPRwire) - Strip away the press-release polish and this is a talent-market land grab wearing an M&A costume. EC-Council, the company behind the Certified Ethical Hacker credential, announced on October 22, 2026, that it has acquired Cyber Insurance Academy, the credentialing body for the cyber and AI insurance industries. Nobody is selling software here. Nobody is selling threat feeds. What changed hands is a certification pipeline, the accreditation rails attached to it, and the trust of an industry that barely understands the technology it now prices. That is the real asset, and the announcement dances around it politely. The stated terms are straightforward. Cyber Insurance Academy keeps its brand, its leadership, and its base in Delaware. Guy Simkin stays on as Co-Founder and CEO. Asaf Armoni remains Co-Founder, CTO and COO. The entity operates as an EC-Council Company. Its programs carry accreditation from CII, ANZIIF, RIBO and NIBA, with continuing education approval in more than 45 U.S. states. That regulatory footprint alone would take years and serious money to replicate from scratch. EC-Council skipped the queue by writing a check, which is exactly what a rational buyer does. The product roadmap tells you more than the deal structure. The flagship Certified Cyber Insurance Specialist designation has been rebuilt as CCIS v2, now covering AI-driven threats, AI governance and AI-related insurance exposures. Beyond that, the Academy plans to expand from cyber insurance into three adjacent territories: AI risk, emerging technology risk, and role-based technology education for insurance professionals. Delivery runs through self-paced learning, certifications, professional designations and enterprise programs aimed at carriers, brokers and managing general agents. Note the sequencing. Cyber stays core, AI rides shotgun, everything else follows. The subtext is a labor arbitrage problem the release actually admits to. Underwriters, brokers, risk managers and claims professionals rarely come from technology backgrounds. Deep technologists almost never speak insurance. Simkin put it bluntly: every insurance professional is now a technology risk professional, whether they realize it or not. EC-Council chose not to invade this market from outside. It bought the organization already closing the gap from within. That is cheaper than building credibility, and credibility is the only currency that matters in credentialing. Watch the competitive ripple. Every cybersecurity training vendor now faces a blueprint for vertical escape. Selling CEH seats to security teams is a crowded, commoditized game. Selling AI-risk fluency to an entire insurance workforce, backed by accreditations in 45-plus states, is a recurring-revenue annuity with regulatory moats. EC-Council also gains a captive distribution channel for its broader Adopt. Defend. Govern. framework. Jay Bavisi framed it as people, process and technology. Translated, it means course content no longer sourced externally, faster catalogue expansion, and margin staying in-house. The next acquisition in this space will not be a training company buying a training company; it will be an insurer or a broker buying the credentialing body outright.

(SeaPRwire) - Nobody at EuroBLECH 2026 will tell you the real story about NexFabric's "human-verified" industrial AI. They have wrapped a diagnostic data capture operation in the language of operator support. The operator still "makes the call." The operator still "confirms" every hardware check. But every diagnosis gets logged. Every procedure gets saved for the next shift. Every new operator's learning curve gets documented in a central production dashboard. That is not augmentation. That is knowledge extraction wearing a lab coat and asking for confirmation at every step. The human verification framing is not a limitation. It is the precision mechanism. It ensures every data point is accurate. It ensures every procedure is actionable. It makes the platform more valuable with every interaction. And every interaction goes into NexFabric's proprietary database. Here is the official story of NexCut. It pairs AI-assisted analysis with operator-confirmed checks for laser cutting diagnostics. Each machine gets a touchscreen operator station and a connected hardware module. The module feeds process signals into the platform. When cut quality drops, NexCut combines those signals with physical checks. The operator inspects the lens, checks gas pressure, verifies focus position, assesses cutting height, examines the nozzle, and evaluates machine stability. NexCut narrows down the likely cause. It explains why. It points to the fix. The operator decides. The official story makes sense. The industry subtext is entirely different. NexFabric is building a proprietary library of manufacturing failure modes and their confirmed resolutions. Every operator interaction becomes training material. Every confirmed diagnosis becomes a reusable procedure. The human verification is the data quality gate. Without it, the dataset would be noisy. With it, the dataset compounds. NexFabric debuted NexCut at EuroBLECH on the stand of Esautomotion, Hall 15, Stand E28, after a first showing at CIIF in Shanghai. That sequencing tells you something. They tested in Shanghai. They are now demonstrating in Germany. They are building the European manufacturing base case while the Asian data foundation is already compounding. The workforce statistics NexFabric cites are real. Germany's Federal Statistical Office projects 12.9 million workers, close to 30% of the workforce, will reach retirement age by 2036. Italian companies reported difficulty filling 47.8% of planned hires. CNC operators and welders are among the hardest roles to fill, according to a CGIA analysis of Unioncamere Excelsior data. These are genuine problems in European manufacturing. NexFabric is not lying about them. The proof of concept at Soluzioni Markaurelio S.r.l. in Avezzano, Italy, is testing specific targets. Average guided diagnosis of 7 to 11 minutes. A 50 to 70% reduction in setup time. Reduced startup scrap and machine stoppages. New operators working independently within two to four weeks. Those numbers sound like a productivity improvement story. Read them as a replacement clock. Two to four weeks is not how long it takes to develop a decade of machine intuition. The veteran operator spent years learning by watching sparks and feeling vibration and listening to cutting sounds. NexCut compresses that learning curve to weeks. That compression is not neutral. It accelerates the point at which the original knowledge holder becomes economically dispensable. NexFabric is not solving the knowledge transfer problem. They are narrowing the transfer window until the transfer becomes unnecessary. And once the window closes, the operator who held the knowledge for decades has no role left. The endgame is visible. Industrial AI companies positioning themselves as human-centered are building proprietary diagnostic datasets that will eventually make the human layer optional. The architecture already contains the seeds of that transition. Start with human verification because model confidence is not yet sufficient. Tighten the decision guidelines as the dataset expands. Phase out confirmation steps once confidence thresholds are met across enough failure scenarios. NexFabric plans to work with multiple industrial partners and dealers to broaden access. That distribution strategy matters. Each new partner means more machines connected. Each connected machine means more diagnostic data flowing into the platform. Each data point means higher confidence in the model. Higher confidence means fewer human checks required. The supply chain question is not whether operators will accept guided diagnostics at the machine. That adoption piece is trivial. The supply chain question is whether laser cutter manufacturers, Esautomotion among them, understand what they are becoming at shows like EuroBLECH. They are not just distribution channels for an aftermarket product. They are becoming the on-ramp to a platform that will eventually own the full relationship between their machines, their operators, and their process knowledge. The person who decides what to cut and how is being slowly extracted from that equation. They simply do not know it yet. NexFabric CEO Stefano D'Andria said NexCut helps and teaches, and that the decision always stays with the person at the machine. That is true today. It will not be true forever. The platform is designed to outgrow the human in the loop. That is what proprietary diagnostic data does when it compounds across enough machines and enough failures and enough shifts.

(SeaPRwire) - Here's my honest read on IEONA GeneAKG®. It's either the most important longevity compound since rapamycin, or it's the most skillfully written supplement press release of 2026. The product comes from Hanmi Life Sciences under NEXTEYE Group, a KOSDAQ-listed company (137940.KQ). The pitch is bold. AKG, a TCA cycle intermediate, supposedly outperforms NMN on NAD+ and sirtuin levels. The team is led by a Harvard-trained doctor. And David Sinclair has "reportedly acknowledged" its potential. Notice that word. Reportedly. It appears twice in the release, doing enormous amounts of work. Strip the adjectives and here's what actually exists. In 2020, the team published animal research showing GeneAKG increased NAD+ and sirtuin protein levels, with effects on mitochondrial ATP production. Third-party evaluations reported a 44.8% reduction in reactive oxygen species, up to a 53.2% increase in telomerase activity, and up to 77% higher SPNS1 gene expression. The formula stacks GeneAKG with fisetin for cellular clearance and pterostilbene for energy production. There are also gender-specific versions. Men's gets saw palmetto and zinc. Women's gets phytoestrogen-like compounds. Now the clinical claim, which deserves its own paragraph. A Phase I trial at NewMed Hospital in the US reportedly showed patients with chronic conditions improving across 13 common chronic diseases, with 128 clinical indicators returning to normal ranges. I've covered longevity biotech for years. Phase I trials are safety studies. They are not designed to demonstrate efficacy across thirteen diseases. One trial, one hospital, thirteen conditions, 128 normalized markers. That pattern should make any careful reader pause. Extraordinary breadth like that usually signals marketing ambition, not validated biology. Here's the macro game. The post-NMN regulatory chill in the US left a vacuum in the consumer longevity market. Brands need a successor molecule with a plausible mechanism and a clean story. AKG fits perfectly. It has real biochemistry behind it, aging-related decline is documented, and it's not tangled in the FDA's NMN drug-exclusion fight. So Korean manufacturers with KOSDAQ listings are positioning early, wrapping the molecule in "world-first patented" framing and gender segmentation. That's not science strategy. That's shelf-space strategy dressed in a lab coat. The competitive moat claim is thinner than it sounds. Fisetin, pterostilbene, saw palmetto, zinc — these are commodity nutraceuticals available from any contract manufacturer in Gyeonggi-do or New Jersey. The defensibility rests entirely on the proprietary GeneAKG processing and the 2020 animal data. If independent labs replicate the NAD+ and telomerase findings, Hanmi Life Sciences has a genuine asset. If they don't, this becomes another longevity brand living off affiliate marketing and a Harvard name-check. The next eighteen months of independent replication will decide which. Watch for whether the peer-reviewed human data ever materializes in a journal anyone has heard of — that's the only tell that matters.

(SeaPRwire) - The whole flexible filament market in FDM printing has operated on a single compromise for years. You pick either a material that prints easily and recovers its shape poorly, or one that bounces back beautifully but chews through extruders and slows production to a crawl. That tension defines every product decision a maker or manufacturer makes. eSUN sees it clearly. The company is positioning its new TPE-95A not as another incremental upgrade but as the answer to that old tradeoff. This is what happens when a manufacturer finally decides to stop catering to the middle of the market. Here are the numbers eSUN is putting on the table. Rebound rate tops out at 58 percent, which the company says is 93 percent higher than its own TPU-95A. Printing speed reportedly jumps up to 137 percent faster. Abrasion drops by nearly 30 percent. Hardness sits at 95A, sitting right in the zone where phone cases and watch bands live. Performance remains stable down to minus 30 degrees Celsius. Fatigue resistance and low compression set are called out as key durability features, along with yellowing resistance. The company points to real end-use applications like anti-slip components and functional flexible parts rather than abstract demos. This is not a lab curiosity. These are production-grade claims meant for shops that run parts daily. What matters most practically is what this means for a printer running Bambu Lab hardware. Firmware presets are built in under the TPU Generic and Bambu categories. That ecosystem lock-in is deliberate and effective. Printers that already live inside that closed loop get a frictionless path to adoption. Outside of it, users still face the age-old flexible filament problems of proper drying, stable feeding, and flow ratio calibration. The material does not erase the mechanical realities of extruding elastomers. It just shifts the balance toward recoverable elasticity at higher throughput. That is a meaningful operational change for anyone stamping out cushioning structures or wear-resistant straps on a regular schedule. The strategic read is straightforward. If these claims hold up in independent testing and production runs, TPU suppliers face margin compression and a re-evaluation of their product roadmaps. Flexible filament buyers now have a credible alternative that does not sacrifice speed for elasticity. The supply chain will sort itself out through price competition and adoption curves, not through announcements. Until then, the question is whether eSUN can scale consistent quality across larger spool runs and wider printer compatibility beyond the Bambu ecosystem. That is where most flexible material launches stall quietly.